Answers are grounded in this paper and cite their sources.
Case series reports the safety of extended rezafungin administration in two patients with azole-resistant fungal infections, highlighting its potential utility for deep tissue disease.
Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia. Few data are available about the long-term use of rezafungin and its use for deep infections like endocarditis and osteomyelitis. We describe our experience with its prolonged use in two azole-resistant
No takes yet. Share an insight, caveat, or question.
Ponta et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: